ArticleJournal for immunotherapy of cancer2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia.Frontiers in oncology · 2024Pooled it
- Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma.Blood advances · 2025Article
- Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.Scientific reports · 2025Article
- Article
- Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell linesFrontiers in immunology · 2024Article
- Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.Cancer letters · 2023Article
- Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.The Journal of clinical investigation · 2023Article
- Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy.International journal of hematology · 2023Review
- Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.Blood advances · 2023Article
- The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.American journal of hematology · 2023Review
- β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib.Oncology letters · 2022Article
- Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.Cancers · 2022Review
- The LncRNA RP11-301G19.1/miR-582-5p/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K/AKT signalling pathway.Cancer gene therapy · 2022Article
- Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma.Frontiers in oncology · 2022Article
- Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews.Frontiers in oncology · 2022Article
- Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.Blood cancer discovery · 2021Article
- Review
- Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.Frontiers in oncology · 2021Review
- HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma.Frontiers in oncology · 2021Article
- Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 1 country.
Funding
Abstract
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.